ÂÜÀòÂÒÂ×

Gary Johnson is the Vice President, Regulatory Affairs, Clinical Research and Health Economics & Reimbursement for Abbott’s Cardiovascular and Neuromodulation Businesses. He was appointed to this role in September, 2016. Prior to assuming his current position, Gary served as Divisional Vice President (DVP), Global Clinical Research, Regulatory Affairs and HEOR for Abbott’s Vascular Business in Santa Clara, California. Additionally, he held the role of DVP, Technical Operations (R&D) at Abbott Vascular. Gary lead the Preclinical, Clinical and Regulatory Affairs functions to the successful approval and launch of Xience V, Abbott Vascular’ s first Drug Eluting Stent. This product was approved in record time, demonstrated clinical superiority over the competition and became the Market Leader. Gary has over 30 years of medical products business, research and development, quality, regulatory affairs, clinical research and health-economics/reimbursement experience. He has held various positions at American Hospital Supply Corporation, Baxter International, Eli Lilly, Guidant Corporation and Abbott. Gary holds a Master of Science degree in Cellular Physiology and a Bachelor’s of Arts degree in Biological Science from the University of California, Santa Barbara. He also holds a graduate SEP certificate from the Stanford Graduate School of Business.